HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT04547985

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

This study has public registry information. It focuses on prolonged grief disorder and currently lists study information in the United States.

Prolonged grief disorderDrugOver 18 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Naltrexone HCl 50 MG Oral Tablet may be useful for adults experiencing prolonged grief disorder.

What would participation involve?

Participants may receive Naltrexone HCl 50 MG Oral Tablet, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with prolonged grief disorder.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: January 5, 2021
Recruitment status
Terminated
Enrollment listed in the registry
9
Sponsor
Weill Medical College of Cornell University
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT04547985
Official title
Naltrexone Treatment for Prolonged Grief Disorder: A Pilot Study

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT04547985. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Terminated

New York

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Prolonged Grief Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Weill Medical College of Cornell University.

Does this study involve medication?

The study includes Naltrexone HCl 50 MG Oral Tablet and Placebo.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
TerminatedNCT06140420

Naltrexone for Prolonged Grief Disorder

This study has public registry information. It focuses on prolonged grief disorder and currently lists study information in the United States.